Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Low levels of growth hormone may contribute to growth defects in cystic fibrosis

A new study using a pig model of cystic fibrosis (CF) suggests that low levels of a growth promoting hormone at or before birth may contribute to growth defects in patients with CF.

10 Nov 2010

mHealth Alliance annual summit kicks off with $1M HP donation, discussion of improving maternal, child health

The mHealth Alliance on Monday at its summit in Washington, D.C., "announced a two-year $1 million aggregate donation from HP" aimed at furthering the alliance's goal of delivering quality health care "at the furthest reaches of wireless networks and mobile devices," mobihealthnews reports.

10 Nov 2010

Redpoint Bio decreases third quarter net loss to $1.8 million

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the three months and nine months ended September 30, 2010.

9 Nov 2010

Mobile technology improves diagnosis and treatment for mothers, newborns and children

Simple mobile technology, like basic cell phones, can be used to save the lives of mothers in childbirth, and improve the care of newborns and children, reaching underserved populations in remote areas.

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010

Arena third quarter net loss increases to $36.3 million

Arena Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Arena also reported earlier today top-line results from its lorcaserin Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial.

9 Nov 2010

Childhood abuse increases risk of type 2 diabetes in women: Study

A new study of nearly 70,000 women found a clear association between abuse in childhood and adolescence and the risk of type 2 diabetes in adult women.

9 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

Researchers identify key step in metabolic pathways linked to diabetes and cancer

United States and Japanese researchers have identified a key step in metabolic pathways linked to diabetes and cancer. The study on activation of the protein complex TORC 2 was published online in the journal Current Biology Oct. 28.

8 Nov 2010

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.

7 Nov 2010

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Lifestyle changes and natural supplements can control blood sugar levels

The holiday season can make it challenging for people with diabetes to keep their blood sugar levels stable. Diabetes expert, Dr. Isaac Eliaz recommends prevention through a number of lifestyle changes and natural supplements.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.

3 Nov 2010

Einstein College's new website features latest information on aging research

Albert Einstein College of Medicine of Yeshiva University has launched SuperAgers.com, a new website that features the latest information on more than a decade of aging research at Einstein.

2 Nov 2010

AGD encourages diabetic patients to pay attention to oral health

According to the U.S. Centers for Disease Control and Prevention, diabetes affects nearly 24 million people in the United States. In observance of National Diabetes Month, the Academy of General Dentistry (AGD) encourages those with diabetes to pay extra attention to their oral health.

2 Nov 2010

Wireless test solutions company LitePoint joins Continua Health Alliance

LitePoint Corporation, the leader in wireless test solutions, announced today it has joined Continua Health Alliance, along with other technology leaders.

1 Nov 2010

Biodel receives FDA CRL for Linjeta NDA

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) requesting additional information regarding the company's new drug application (NDA) for Linjeta™ (human insulin [rDNA origin]) injection 100IU/mL for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control.

1 Nov 2010

Sugar in excess leads to complications

In light of Diabetes Awareness Month, many people are showing increased interest in the topic of sugar and sugar alternatives. With the various forms of sugar available table sugar, high-fructose corn syrup, agave, and honey understanding the differences between sugars and their effects on the body is not all sweet.

1 Nov 2010

Insulin News and Research

Further Reading

Low levels of growth hormone may contribute to growth defects in cystic fibrosis

mHealth Alliance annual summit kicks off with $1M HP donation, discussion of improving maternal, child health

Redpoint Bio decreases third quarter net loss to $1.8 million

Mobile technology improves diagnosis and treatment for mothers, newborns and children

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena third quarter net loss increases to $36.3 million

Childhood abuse increases risk of type 2 diabetes in women: Study

Potential new biomarkers for very early prostate cancer

Researchers identify key step in metabolic pathways linked to diabetes and cancer

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Phase III study suggests CYCLOSET tablets improve glycemic control

Lifestyle changes and natural supplements can control blood sugar levels

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Einstein College's new website features latest information on aging research

AGD encourages diabetic patients to pay attention to oral health

Wireless test solutions company LitePoint joins Continua Health Alliance

Biodel receives FDA CRL for Linjeta NDA

Sugar in excess leads to complications

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News